Further studies could investigate the p53 protein expression in PT-DLBCL and novel therapies for the TP53mut subtype, such as adding decitabine, a DNA methylation inhibitor, to the standard of care, which improved the clinical outcomes of TP53mut patients with systemic DLBCL in a phase II clinical trial (30). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.